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Dotter and Judkins (1) in 1964 reported the use of coaxial 
dilating catheters in remodeling the lumen of obstructed 
peripheral arteries. In Zurich in 1977 Griintzig (2) reported 
the first transcutaneous transluminal coronary angioplasty 
using a system for mechanically dilating a stenosed epicar•
dial artery. Since the report by Griintzig, tens of thousands 
of patients (estimated> 100,000) have been treated for ob•
structive coronary disease with percutaneous transluminal 
coronary angioplasty. Initially only patients with single ves•
sel disease were considered for this form of therapy, and 
they continue to be considered "ideal candidates" for coro•
nary angioplasty (3). Despite the absence of objective clin•
ical trial data in support of coronary angioplasty, enthusiasm 
for the procedure is such that the technique was extended 
to include patients with multivessel disease. 
In this issue of the Journal, Vandormael et al. (4) report 
their experience using percutaneous transluminal coronary 
angioplasty in patients with multivessel disease. The authors 
are to be complimented on their results and their methods 
of presenting their data. By sharing this experience it is 
hoped that the benefit/risk ratio of such a procedure might 
be better understood. In the short span of less than a decade 
much has been written and learned about percutaneous trans•
luminal coronary angioplasty. First, it is clear that this pro•
cedure can be performed; and second, with improvement in 
technology and technique the "success rate" has increased. 
Unfortunately, it is also true that a learning curve must be 
traversed before results similar to those reported by Van•
dormael et al. can be achieved. 
Success rate. The "primary success rate" reported var•
ies from 60 to 90% and is mainly a reflection of the instru•
ments used and level of experience of the angiographer. 
The definition of a primary success has changed since the 
first report by Griintzig. Initially success was defined as a 
10% or greater reduction of the stenosis, a decrease in pres•
sure gradient and an improvement in clinical status (5). This 
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definition was later modified by Griintzig to include patients 
whose stenosis was decreased by 20% or greater and who 
did not need coronary artery bypass surgery during their 
hospitalization. A decrease in gradient across the stenotic 
segment was not part of the definition. The National Heart 
Lung, and Blood Institute has adopted this definition of 
primary success for its Percutaneous Transluminal Coronary 
Angioplasty Registry (6). This definition-namely, a re•
duction of the stenosis by a specific percent-has been ac•
cepted without challenge, despite the knowledge that esti•
mation of the severity of stenotic segments in the coronary 
circulation by angiography is subject to considerable error 
(7). 
Benefits of coronary angioplasty. The reported benefits 
of coronary angioplasty include relief of angina, patency of 
the artery, improved left ventricular function, improved 
myocardial perfusion, improved exercise performance and 
lower cost. 
Lessening of the anginal syndrome is reported in a high 
proportion of patients (approximately 90%) by most phy•
sicians reporting on coronary angioplasty. Indeed, the pri•
mary goals of treatment are to relieve angina and improve 
the quality of life. It is uncertain, however, whether the 
procedure will have a significant effect on either preventing 
myocardial infarction or prolonging life. The results of three 
randomized trials comparing coronary artery bypass surgery 
with medical treatment demonstrated increased survival time 
in only a small subset of patients, and revealed no effect 
on prevention of myocardial infarction; therefore, there is 
no reason to believe that coronary angioplasty will be able 
to accomplish these goals. 
Studies reporting improved exercise peiformance as as•
sessed by standardized treadmill exercise testing (8), im•
proved left ventricular function as assessed by radionuclide 
an~iographic techniques (9) and improved myocardial per•
fuslOn as assessed by thallium-20r imaging are encouraging 
(8). However, these are all short-term studies and the data 
cannot be extrapolated to long-term results. 
The economic impact of coronary angioplasty versus 
coronary artery surgery has been discussed and reported by 
several institutions with varying results. Reeder et al. (10) 
suggest a 15% decrease in cost. However, in this study the 
cost of the surgeon and operating room on standby was not 
included. Cost studies have been done primarily on patients 
with single vessel disease. With multi vessel disease there 
is less likelihood of complete vascularization and probably 
a higher incidence of restenosis, so the potential cost benefit, 
if present, is minimized. 
Complications. The real cost to the patient includes the 
failure rate, the risk of acute coronary artery occlusion, 
myocardial necrosis, precipitation of coronary artery spasm, 
coronary artery dissection, coronary artery rupture, emer-
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gency and elective coronary artery bypass surgery and the 
other vascular complications that occur. Most important, 
restenosis after coronary angioplasty remains a major problem. 
Coronary artery occlusion complicating coronary angio•
plasty occurs in 2.5 to 5% of patients and usually within 4 
to 6 hours after the procedure (11,12), The occlusion is 
more common with severely stenotic lesions and may occur 
despite apparent "primary success" of the coronary angio•
plasty and despite the use of anticoagulant agents, vasodi•
lators and antiplatelet drugs. 
Acute myocardial infarction occurs in approximately 5% 
of patients after angioplasty (11). In the first 1,500 cases 
reported by the National Heart, Lung, and Blood Institute 
Percutaneous Transluminal Coronary Angioplasty Registry, 
4.8% of patients were reported to have an infarction, with 
the majority occurring within the first 24 hours. Approxi•
mately a third of these patients (39%) had emergency coro•
nary artery bypass grafting and 3% received elective coro•
nary artery bypass grafting. 
Coronary artery dissection occurs in approximately 10% 
of patients (11). Of these, approximately one-third will ex•
perience another major complication such as transmural 
myocardial infarction and the need for emergency coronary 
artery bypass surgery. Two-thirds of the patients with well 
documented coronary artery dissection had no complica•
tions. Contrary to early concern, coronary artery rupture 
(13) and significant distal embolization are very infrequent 
complications. 
Mortality is related primarily to the level of experience 
of the operator. Mortality is approximately 1 % (11,12) and 
was 16 of 1,500 patients in the experience of the National 
Heart, Lung, and Blood Institute Registry. Eleven deaths 
were considered directly attributable to the procedure itself. 
Complications associated with these deaths consisted of left 
main coronary artery dissection, dissection of other coronary 
arteries, coronary artery occlusion, coronary vasospasm and 
emergency coronary artery bypass grafting in patients with 
unstable angina. Five patients died as a result of events that 
were considered probably unrelated to coronary angioplasty, 
and three of these patients had undergone emergency coro•
nary artery bypass surgery. 
Restenosis after coronary angioplasty is frequent and a 
major problem for the patient who has had a "successful" 
dilation. The restenosis rate is approximately 30% and usu•
ally occurs within 6 months (11,14). In the study by Van•
dormael et al. (4), although the numbers were small, the 
restenosis rate was 3 of 9 in asymptomatic patients and 18 
of 22 in those with recurrent angina. There is no clinical 
profile or angiographic study that will predict which patient 
will develop restenosis. There is no established drug regi•
men that prevents restenosis. When a second coronary an•
gioplasty is performed, there may be a higher success rate, 
a lower nonfatal acute myocardial infarction rate, a lower 




and a lower death rate compared with the first procedure. 
For this reason, part of the philosophy of coronary angio•
plasty is to consider the possibility of a second, third and 
fourth procedure. Unfortunately, for a given patient the risks 
of the procedure are additive, and therefore the potential 
advantages over coronary artery bypass surgery, if any, are 
minimized. 
Problems and unanswered questions. What questions 
and problems remain unanswered in spite of the accumulated 
knowledge summarized briefly here? First, despite exten•
sive laboratory and clinical experience, the basic mechanism 
by which coronary angioplasty improves arterial patency 
remains an enigma (15). 
Second, coronary heart disease is complex and to un•
derstand the effect of any intervention, homogeneous sub•
sets must be identified and prospective randomized studies 
performed within this group. From the point of view of a 
clinician, stratification of these patients seems necessary. 
At present, coronary angioplasty is recommended for the 
entire spectrum of patients beginning with the asymptomatic 
patient with an abnormal arteriogram through and including 
the patient with acute myocardial infarction. It is obvious 
that there is a marked variability in the number of vessels 
involved, the number, size and location of lesions and the 
spectrum within each lesion depending on composition of 
lesion, and this must be considered in any evaluative study. 
Third and finally, the most fundamental question has not 
been asked. Does a patient benefit from coronary angio•
plasty in comparison with currently available therapeutic 
regimens? And if so, which subset of patients is most likely 
to benefit? Weare almost a decade late in asking these 
questions, and the answers will not be forthcoming through 
analysis of retrospective, nonrandomized studies. 
We have reached the moment when a self-imposed mor•
atorium should be placed on percutaneous transluminal 
coronary angioplasty. A detailed analysis of all available 
data should be undertaken. Most important, a well designed 
prospective randomized study should be done comparing 
identical groups of patients treated medically, treated with 
coronary angioplasty or treated with coronary artery bypass 
surgery. 
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